CVE-2022-47376

Name: CVE-2022-47376
Creator: NVD / NIST
Published: 2023-06-13T20:15:08.967+00:00
License: https://creativecommons.org/publicdomain/zero/1.0/

HIGHCVSS 7.3/10EPSS 0.16%

Last modified Jun 17, 2026

CVE-2022-47376 is a high-severity vulnerability rated 7.3/10 on the CVSS scale. The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.. EPSS estimates a 0.16% chance of exploitation in the next 30 days.

Description

The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.

Metrics

CVSS 3.1

7.3/10

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L

EPSS Probability

0.16%

5.8th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

Affected Software

Vendor	Product	Versions
Bd	Alaris Infusion Central	>= 1.1, <= 1.3.2

References

Timeline

Published: Jun 13, 2023
Last Modified: Jun 17, 2026
Status: Modified

Frequently Asked Questions

What is CVE-2022-47376?

How severe is CVE-2022-47376?

CVE-2022-47376 has a CVSS score of 7.3/10 (HIGH severity). The EPSS model estimates a 0.16% probability of exploitation in the next 30 days.

How do I fix CVE-2022-47376?

Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

Are you affected by CVE-2022-47376?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST